Key facts
- It has raised $6.9M; the latest was Later Stage VC ($6.3M) in Aug 2025.
- Notable investors include CAV Angels, University of Virginia, 434, Charlottesville Angel Network, Virginia Catalyst.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Lytos
- ·The full record, as it builds
Funding rounds
No funding rounds for Lytos are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lytos
Producer of a biotechnology platform intended to address antimicrobial resistance and improve microbial control across health, food, and environmental applications. The company offers biofilm disruption technology, pathogen elimination capabilities, and chemistry-free microbial control with biofungicides and antimicrobial products, enabling healthcare, agriculture, and environmental industries, to manage persistent pathogens and reduce reliance on chemical treatments.
- Sector
- Healthcare
- HQ
- Waynesboro, VA, United States
- Founded
- 2018
- Employees
- 10
- Website
- lytostech.com/
- Ownership
- Privately Held (backing)
Lytos doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lytos shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lytos in its N-PORT filings yet. We sweep new filings monthly.